Engineering M13 Filamentous Phages to Target Dendritic Cells and Elicit Anti‐Tumour Immunity

Why It Matters

SCP eliminates the need for neoantigen discovery and costly manufacturing, enabling faster, broader deployment of effective cancer vaccines across tumour types.

Key Takeaways

• SCP co-displays DC-targeting peptides and SpyCatcher
• Activates dendritic cells, upregulating co-stimulatory markers
• Generates tumour-specific T cell responses without predefined neoantigens
• Reduces tumour neovascularisation and immune checkpoint expression
• Scalable, low-cost platform enables adaptable cancer immunotherapy

Pulse Analysis

Filamentous M13 phages have long attracted interest as self‑adjuvanting nanocarriers, yet their clinical translation has been hampered by limited antigen versatility and suboptimal immune targeting. The SCP platform resolves these challenges by integrating SpyCatcher‑SpyTag chemistry for rapid, modular antigen attachment and by displaying peptides that home to dendritic cells, the pivotal orchestrators of adaptive immunity. This dual‑function design amplifies antigen uptake and presentation, positioning SCP as a next‑generation vaccine vector that bridges the gap between simplicity of production and potency of response.

Preclinical data across several murine tumour models demonstrate that SCP can be administered either as a prophylactic subcutaneous vaccine or as an intratumoral therapeutic. The vector induces a pronounced inflammatory microenvironment, promotes immunogenic cell death, and releases endogenous tumour antigens, thereby converting “cold” tumours into immunologically hot lesions. Notably, SCP achieves these effects without pre‑selected neoantigens, while simultaneously curbing tumour neovascularisation and down‑regulating checkpoint molecules, which together foster durable, systemic cytotoxic T‑cell immunity capable of preventing relapse.

From a commercial perspective, SCP’s reliance on bacteriophage production confers unparalleled scalability and cost efficiency compared with synthetic peptide or mRNA platforms. Its modular architecture allows rapid swapping of antigens, facilitating swift responses to emerging cancer subtypes or personalized regimens. As the oncology market seeks affordable, off‑the‑shelf immunotherapies, SCP’s blend of manufacturability, adaptability, and robust preclinical efficacy positions it as a compelling candidate for future clinical development and partnership opportunities.